EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
Remo Panaccione 1
Peter D. R. Higgins 2
Gary Lichtenstein 3
Hiroshi Nakase 4
Michelle Kujawski 5
Erica Cheng
Dapo Ilo
Gweneth Levy
Jason Eccleston
Sarah C. Glover 6
Silvio Danese 7
Jean-Frédéric Colombel 8
Stefan Schreiber 9
1 University of Calgary, Calgary, Canada
2 Division of Gastroenterology, University of Michigan, Ann Arbor, United Kingdom
3 University of Pennsylvania School of Medicine, Merion Station, United States
4 Sapporo Medical University School of Medicine, Sapporo, Japan
5 AbbVie, Inc, North Chicago, United States
6 University of Mississippi Medical Center (UMMC), Jackson, United States
7 Humanitas University and Humanitas Research Hospital, IRCCS, Milan, Italy
8 Icahn School of Medicine at Mount Sinai, New York, United States
9 University Hospital Schleswig-Holstein, Kiel, Germany
Topic
IBD
Session
Hit the road JAK: Part 2
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]